Literature DB >> 18962725

Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis.

Naoki Atsuta1, Hirohisa Watanabe, Mizuki Ito, Fumiaki Tanaka, Akiko Tamakoshi, Imaharu Nakano, Masashi Aoki, Shoji Tsuji, Tatsuhiko Yuasa, Hiroki Takano, Hideaki Hayashi, Shigeki Kuzuhara, Gen Sobue.   

Abstract

PURPOSE: To profile the detailed clinical features of sporadic amyotrophic lateral sclerosis (ALS) on large-scale samples in Japan.
METHODS: We assessed the clinical features of sporadic ALS patients in Japan, based on the nationwide registration system of the Ministry of Health, Labor and Welfare of Japan. We described 3,428 new cases registered cases between 2003 and 2006 to analyze initial symptoms and related clinical features, 4,202 cases registered in the single year of 2005 to describe the cross-sectional overview of the ALS patients, and a total of 2,128 cases with tracheostomy positive pressure ventilation (TPPV) from all of the registration data from 2003 to 2006 to describe the features of ALS patients with TPPV.
RESULTS: The patients with an older age at onset progressed more rapidly to the TPPV stage than those with a younger age at onset. The subpopulation of patients with long-standing TPPV showed ophthalmoplegia, while its appearance rate was less in the patients with an older age at onset than in those with a younger age at onset. Furthermore, age at onset strongly influenced the frequency of initial symptoms: dysarthria, dysphagia, neck weakness and respiratory disturbance were more frequent in patients with an older age at onset, while upper or lower limb weakness was observed more frequently in patients with a younger age at onset. In addition, those initial symptoms were still the most prominent at the follow-up stage, suggesting that the initial symptoms determine the major clinical features even in advanced illness.
CONCLUSIONS: Our present study demonstrated that symptomatic features of ALS are strongly influenced by the age at onset by the large scale of samples.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18962725     DOI: 10.1016/j.jns.2008.09.024

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  26 in total

Review 1.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

Review 2.  The phenotypic variability of amyotrophic lateral sclerosis.

Authors:  Bart Swinnen; Wim Robberecht
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

Review 3.  Trends in Research Literature Describing Dysphagia in Motor Neuron Diseases (MND): A Scoping Review.

Authors:  Ashley A Waito; Teresa J Valenzano; Melanie Peladeau-Pigeon; Catriona M Steele
Journal:  Dysphagia       Date:  2017-06-29       Impact factor: 3.438

4.  The effect of autologous bone marrow mononuclear cell transplantation on the survival duration in Amyotrophic Lateral Sclerosis - a retrospective controlled study.

Authors:  Alok K Sharma; Hemangi M Sane; Amruta A Paranjape; Nandini Gokulchandran; Anjana Nagrajan; Myola D'sa; Prerna B Badhe
Journal:  Am J Stem Cells       Date:  2015-03-15

5.  Stratification of ALS patients' survival: a population-based study.

Authors:  Benoît Marin; Philippe Couratier; Simona Arcuti; Massimiliano Copetti; Andrea Fontana; Marie Nicol; Marie Raymondeau; Giancarlo Logroscino; Pierre Marie Preux
Journal:  J Neurol       Date:  2015-10-30       Impact factor: 4.849

6.  ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Authors:  Hiroshi Mitsumoto; Pam Factor-Litvak; Howard Andrews; Raymond R Goetz; Leslie Andrews; Judith G Rabkin; Martin McElhiney; Jeri Nieves; Regina M Santella; Jennifer Murphy; Jonathan Hupf; Jess Singleton; David Merle; Mary Kilty; Daragh Heitzman; Richard S Bedlack; Robert G Miller; Jonathan S Katz; Dallas Forshew; Richard J Barohn; Eric J Sorenson; Bjorn Oskarsson; J Americo M Fernandes Filho; Edward J Kasarskis; Catherine Lomen-Hoerth; Tahseen Mozaffar; Yvonne D Rollins; Sharon P Nations; Andrea J Swenson; Jeremy M Shefner; Jinsy A Andrews; Boguslawa A Koczon-Jaremko
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-02-24       Impact factor: 4.092

7.  Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis.

Authors:  Daichi Yokoi; Naoki Atsuta; Hazuki Watanabe; Ryoichi Nakamura; Akihiro Hirakawa; Mizuki Ito; Hirohisa Watanabe; Masahisa Katsuno; Yuishin Izumi; Mitsuya Morita; Akira Taniguchi; Masaya Oda; Koji Abe; Kouichi Mizoguchi; Osamu Kano; Satoshi Kuwabara; Ryuji Kaji; Gen Sobue
Journal:  J Neurol       Date:  2016-04-15       Impact factor: 4.849

8.  Respiratory and nutritional support in amyotrophic lateral sclerosis.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2014-02       Impact factor: 3.598

9.  Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany.

Authors:  Angela Rosenbohm; Mingsheng Liu; Gabriele Nagel; Raphael S Peter; Bo Cui; Xiaoguang Li; Jan Kassubek; Dietrich Rothenbacher; Dorothée Lulé; Liying Cui; Albert C Ludolph
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

Review 10.  Current pathways for epidemiological research in amyotrophic lateral sclerosis.

Authors:  Pam Factor-Litvak; Ammar Al-Chalabi; Alberto Ascherio; Walter Bradley; Adriano Chío; Ralph Garruto; Orla Hardiman; Freya Kamel; Edward Kasarskis; Ann McKee; Imaharu Nakano; Lorene M Nelson; Andrew Eisen
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-05       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.